Thermo Scientific™ Sensititre™ EUMDR2F
Confidently perform antimicrobial susceptibility testing (AST) of clinically relevant non-fastidious Gram-negative isolates on a single comprehensive panel now containing Aztreonam / Avibactam, Cefepime / Emnetazobactam, and Sulbactam / Durlobactam.
Receive your quote directly from the manufacturer.
Confidently perform antimicrobial susceptibility testing (AST) of clinically relevant non-fastidious Gram-negative isolates on a single comprehensive AST panel now containing Aztreonam / Avibactam, Cefepime / Emnetazobactam, and Sulbactam / Durlobactam. Generate clinically impactful data, detect emerging resistance, and help guide timely and accurate antimicrobial therapy by utilising micro-broth dilution - the gold standard1 phenotypic method for AST.
This convenient panel meets EUCAST breakpoints for a broad range of relevant second line antimicrobials, including Ceftazidime / Avibactam, Colistin, Eravacycline, Imipenem / Relebactam, and Meropenem / Vaborbactam.
Key features and product benefits:
- Deliver consistent turnaround times to support earlier clinical decision-making and targeted therapy, particularly in critical infections such as sepsis.
- Monitor susceptibility among critical Gram-negative isolates with full-range, accurate MIC values for a broad array of clinically relevant antimicrobics.
- For ultimate flexibility automated or manual read options are available with one panel; compatible with all Sensititre™ instrumentation options - designed to be modular in order to meet the unique needs of individual lab space, workload, and budget requirements.
- Eliminate inventory control concerns with extended shelf life (24-months), and room temperature storage.
- Individual packaging allows testing of one sample at a time, with reduced waste.
Not all products are available for sale in all territories. Please inquire.
For In Vitro Diagnostic Use.
1. Jayol A, Nordmann P, Andre C, Poirel L, Dubois V. Evaluation of three broth microdilution systems to determine colistin susceptibility of Gram-negative bacilli. J Antimicrob Chemother. 2018; 73: 1272-1278. PubMed
Brochures
Sensititre EUMDR2F panel supports advanced MIC testing for multidrug-resistant Gram-negative bacteria
This resource presents the layout of the Thermo Scientific™ Sensititre™ EUMDR2F broth microdilution panel, developed for antimicrobial susceptibility testing (AST) of non-fastidious Gram-negative organisms, including multidrug-resistant strains. The panel enables minimum inhibitory concentration (MIC) determination using standardized broth microdilution aligned with EUCAST guidelines.
The EUMDR2F panel includes a comprehensive selection of second line and newer antimicrobial combinations, such as aztreonam/avibactam, cefepime/enmetazobactam, and sulbactam/durlobactam, alongside established agents like colistin, eravacycline, and meropenem/vaborbactam. This expanded coverage supports testing of resistant pathogens and informs treatment decisions in clinical microbiology workflows.
Resource details:
- Resource type: Product brochure
- Page count: 2
- Read time: 3 mins
CLINICAL24: Carbapenem resistance in 2026: From rapid detection to actionable susceptibility results
Monday, November 30 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST
From resistance detection to actionable AST: Navigating the changing landscape of Gram-negative resistance.
Antimicrobial resistance among Gram-negative organisms continues to present significant challenges for clinical microbiology laboratories. As resistance mechanisms evolve and new antimicrobial therapies become available, laboratories need to consider how best to translate resistance detection into clinically relevant antimicrobial susceptibility results.
Join Professor Laurent Dortet and Professor Axel Hamprecht, internationally recognized experts in antimicrobial resistance and clinical microbiology, for a practical discussion on the evolving landscape of Gram-negative resistance and its implications for antimicrobial susceptibility testing (AST).
The speakers will explore current and emerging resistance mechanisms, including carbapenem resistance, and discuss what resistance-mechanism detection can—and cannot—tell the laboratory. They will examine the complementary role of phenotypic AST and MIC determination, particularly when managing challenging multidrug-resistant organisms and newer antimicrobial treatment options.
Through practical examples and case-based discussion, the webinar will also consider how laboratories can adapt their AST strategies as resistance patterns, antimicrobial formularies, and breakpoint requirements evolve.
The session will conclude with an expert discussion and live Q&A, providing attendees with an opportunity to put their questions directly to Professors Dortet and Hamprecht.
Register to explore how the clinical microbiology laboratory can move from identifying resistance to generating actionable susceptibility information in an increasingly complex Gram-negative landscape.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
- Format: Expert presentation followed by live Q&A
Can't attend live?
Register today and you will receive access to the recording after the webinar, allowing you to revisit key insights and share learning across your team.
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Certificate of attendance
All attendees who join the live webinar will automatically receive a certificate of attendance, including a summary of key learning outcomes, to support their continuing professional development.
If you watch the on-demand recording, a certificate of attendance can be requested by emailing editor@selectscience.net.
About CLINICAL24
CLINICAL24 is a global initiative dedicated to exploring the challenges facing modern clinical laboratories and highlighting the technologies, expertise, and collaborative approaches helping to improve patient care worldwide.
MIC data and AST confidence shape modern AMR stewardship
As Gram-negative resistance becomes more complex, laboratories and clinicians are working together to turn susceptibility data into more targeted treatment decisions
